DOSAGE AND DURATION
Initial dose: 100 to 200 mg once daily in the morning or 100 mg twice daily (morning and lunch). Dose may be titrated by 100 mg weekly to effect or maximum dose: 400 mg/day (in divided doses). Treatment duration ranged from 2 to 8 weeks in controlled trials and up to 8 months in case reports.
RESULTS
The use of modafi nil in the treatment of PDrelated somnolence has been studied in several small controlled trials enrolling fewer than 100 Parkinson patients, demonstrating confl icting results. [4] [5] [6] [7] Data from open trials and case reports suggest limited benefi t. [8] [9] [10] [11] Several national and international guidelines state that modafi nil should be considered in the management of PD-related somnolence, recognizing that evidence is confl icting with improvement noted in subjective sleep ratings but inconsistent or no benefi t observed in objective sleep parameters. 2, 3, 12, 13 Evaluating the same published clinical data, the Scottish Intercollegiate Guidelines Network does not recommend the use of modafi nil in the management of excessive daytime sleepiness. 14
Guidelines

American Academy of Neurology
The American Academy of Neurology (AAN) guidelines on the management of nonmotor symptoms of PD recommend that modafi nil should be considered for patients to improve subjective perception of EDS. This recommendation is based on the review of 3 controlled trials 4-6 that demonstrated effectiveness in improving patient perception of wakefulness without actual improvement in objective sleep measurements. These guidelines also state that there is insuffi cient evidence to support or refute a safety benefi t in patients with PD with EDS who engage in activities where sleepiness poses a potential danger (eg, driving). 12 This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specifi c drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specifi c use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
American Academy of Sleep
The American Academy of Sleep (AASM) practice parameters for the treatment of narcolepsy and other hypersomnias of central origins recommend that the use of modafi nil may be effective in the treatment of EDS due to PD based on confl icting data from 3 trials 4,6,8 and committee consensus. This recommendation is presented as an option, defi ned as a patient-care strategy that refl ects uncertain clinical use and implies either inconclusive or confl icting evidence or confl icting expert opinion. The conclusion on the use of modafi nil was based on confl icting data regarding the impact on subjective and objective measurements of sleep. 2
Parkinson Society of Canada
The Canadian guidelines on PD 13 state that modafi nil may be considered for use in hypersomnolence associated with PD. This recommendation is based on formal consensus or expert opinion. Review of confl icting data from 3 controlled trials 4-6 was described.
European Federation of Neurological Society
The European Federation of Neurological Society (EFNS) evidence-based review of the management of PD recommends that modafi nil may be added to other measures in the management of daytime somnolence and sudden onset of sleep attacks. Other management techniques include the assessment of nocturnal sleep disturbances; improvement of nocturnal sleep by reducing akinesia, tremor, and urinary frequency; recommendation to stop driving, reduce/ discontinue sedative drugs; decrease dopaminergic drugs (mainly dopamine agonists); and consider a switch to other dopamine agonists as all dopaminergic drugs may induce daytime somnolence. The addition of other wake-promoting agents such as methylphenidate may be also considered. 3
Scottish Intercollegiate Guidelines Network
The Scottish Intercollegiate Guidelines Network (SIGN) guidelines regarding the management of PD suggest that the treatment of excessive daytime sleepiness should focus on the determination of a reversible factor (eg, depression, poor sleep hygiene, drugs). Based on the data from 3 controlled trials, 4-6 the guidelines did not recommend the use of modafi nil in the management of EDS. It should be noted that the same trials were evaluated in other clinical guidelines.
Controlled Trials
An additional controlled trial has been published after most guidelines were issued. A small doubleblinded, placebo-controlled trial evaluated the effect of modafi nil on PD-related fatigue in 19 adult patients and also included somnolence measurements in its methodology. Patients received either modafi nil (100 mg twice daily) or placebo for 2 months. Fatigue was measured via alternate fi nger tapping, Multidimensional Fatigue Inventory scale, depression scale, and Epworth Sleepiness Scale (ESS). Three subjects in the modafi nil group withdrew due to adverse events (hematuria, memory loss, loss of balance, urinary frequency, soft stool and fl atulence, early awakening) and were not included in the analysis. At the end of 2 months, individuals had a signifi cantly higher tapping frequency than they did at baseline (185 vs 197 strikes/ min; P < .05). They also had less fatigability in fi nger tapping and lower but not signifi cant reduction in ESS scores (8.3 vs 6.0; P < .12). The authors concluded that although physical fatigability may be improved, objective measurements of symptoms may not be affected. 7
Noncontrolled Trial
An additional open-label trial has been published after most guidelines were issued. In an open-label trial, 10 institutionalized elderly patients (at least 70 years old; mean age: 79.7 years) with PD and EDS received modafi nil for 3 weeks. Initial doses were 100 mg in the morning for 1 week followed by 100 mg twice daily (morning and lunch) for the next 2 weeks. All patients had a greater than 10 score on the ESS. The mean ESS scores at 3 weeks was signifi cantly reduced when compared to baseline levels (10.6 vs 12.7, respectively; P < .001). Global assessment scores and appetite were also improved. No adverse events or changes in weight were observed. 9
SAFETY
This is a limited safety profi le. Refer to package labeling for complete prescribing information (eg, Warnings/Precautions, Adverse Reactions, Drug Interactions).
Adverse events related to modafi nil therapy have been headache, dry mouth, dizziness, back pain, and generalized pruritus. In some reports, symptoms have decreased when dosages were reduced. 8 Guidelines have noted that the benefi t risk ratio for the use of modafi nil in the management of PDrelated EDS is not well documented because of the small numbers of patients treated in published trials. 2
THERAPY CONSIDERATIONS
The use of modafi nil in the treatment of PDrelated somnolence has been studied in controlled and noncontrolled settings with confl icting results. Several national and international guidelines recommend that modafi nil should be considered in the management of PD-related somnolence, recognizing that evidence is confl icting with improvement noted in subjective sleep ratings but inconsistent or no benefi t observed in objective sleep parameters. Evaluating the same published clinical data, the SIGN does not recommend the use of modafi nil in the management of PD-related excessive daytime sleepiness.
